Desmopressin vs Icotrokinra
Overview
Desmopressin is primarily a hormonal peptide, while Icotrokinra is used for immune support.
This page compares Desmopressin and Icotrokinra across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Desmopressin | Icotrokinra | |
|---|---|---|
| Category | Hormonal | Immune Support |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) | — |
| Frequency | Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia) | — |
| Reported benefits | central diabetes insipidus management, primary nocturnal enuresis in children, nocturia due to nocturnal polyuria, perioperative hemostasis in mild hemophilia A, hemostasis in Type I von Willebrand disease, management of polyuria following head trauma or pituitary surgery | — |
| Reported side effects | hyponatremia (boxed warning), headache, facial flushing, nausea, abdominal cramps, fluid retention, hypotension, reflex tachycardia, hypertension, tachyphylaxis with repeated dosing, rare anaphylaxis | — |
Key differences
Primary use. Desmopressin is categorised under Hormonal, while Icotrokinra falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Desmopressin: FDA-approved. Icotrokinra: FDA-approved.
Dosing. Desmopressin is typically dosed at 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) (Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia)). Typical dosing for Icotrokinra is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking Desmopressin and Icotrokinra has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Desmopressin and Icotrokinra?
- Desmopressin is primarily a hormonal peptide, while Icotrokinra is used for immune support. Desmopressin is FDA-approved for one or more indications, whereas Icotrokinra is FDA-approved for one or more indications.
- What is Desmopressin used for?
- Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Can you take Desmopressin and Icotrokinra together?
- Some users combine peptides within a single protocol, but stacking Desmopressin and Icotrokinra has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Desmopressin or Icotrokinra FDA-approved?
- Desmopressin is FDA-approved for one or more indications. Icotrokinra is FDA-approved for one or more indications.
Read the full articles
- Desmopressin — full monograph: mechanism, research, dosing & references
- Icotrokinra — full monograph: mechanism, research, dosing & references